Q32 Bio Inc. Common Stock (QTTB)

PHARMACEUTICAL PREPARATIONS

Q32 Bio Inc. Common Stock (QTTB) is listed on Nasdaq, where it has traded since March 26, 2024.

Listed On
Nasdaq
Listed Since
March 26, 2024
Employees
22
Market Cap
$261M

About Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 69 institutions reported holding QTTB, with 22.2 million shares worth $282.6 million in aggregate. The largest reported holder was Orbimed Advisors, with 4.1 million shares worth $52.6 million. Of the 5 largest holders listed below, 3 opened new positions in QTTB and 2 added shares during the quarter.

InstitutionSharesValueQuarter change
Orbimed Advisors4,127,987$53MAdded 83.22%
Boxer Capital Management3,149,310$40MNew position
Atlas Venture Life Science Advisors2,717,106$35MAdded 29.87%
Bvf Inc/IL2,350,000$30MNew position
RA Capital Management,2,332,457$30MNew position

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is QTTB?

Q32 Bio Inc. Common Stock (QTTB) is listed on Nasdaq, where it has traded since March 26, 2024.

Who are the largest institutional holders of QTTB?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of QTTB were Orbimed Advisors, Boxer Capital Management and Atlas Venture Life Science Advisors.

How many institutions own QTTB?

69 institutions reported a position in QTTB for the quarter ended June 30, 2026, worth $282.6 million in total.

Did institutions buy or sell QTTB last quarter?

Of the 5 largest reported holders, 3 opened new positions in QTTB and 2 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for QTTB.

Every reported institutional holder, plus insider and congressional trades in QTTB, on SentiSense.